# Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March Canonical URL: https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-in-1eafd2ef Ticker: CRNX Company: Crinetics Pharmaceuticals Source: Crinetics Pharmaceuticals Published: 2026-02-05 21:05 EST ## Summary Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in... ## Article Body Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern Time Webcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events . If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 ## Recent Company News - 2026-06-30 20:05 EST — [Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-4b8a9657) — Source: Crinetics Pharmaceuticals - 2026-06-14 20:30 EST — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-c1c2be50) — Source: Crinetics Pharmaceuticals - 2026-06-14 18:45 EST — [Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control](https://biopharmsignal.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine--eaa37cc2) — Source: Crinetics Pharmaceuticals - 2026-06-02 20:05 EST — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-3a497246) — Source: Crinetics Pharmaceuticals - 2026-06-02 08:55 EST — [Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations](https://biopharmsignal.com/news/CRNX/crinetics-paradigm-shifting-portfolio-and-pipeline-on-display-at-endo-2026-with--b53db9a2) — Source: Crinetics Pharmaceuticals ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)